{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:29:31Z","timestamp":1785774571823,"version":"3.56.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"S4","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johannes Kepler University Linz"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Akute Stoffwechselentgleisungen k\u00f6nnen f\u00fcr Erwachsene in Abh\u00e4ngigkeit von ihrem Ausma\u00df lebensbedrohlich sein. Dementsprechend sind eine rasche umfassende Diagnostik und Therapie sowie eine enge \u00dcberwachung der Vitalparameter und Laborbefunde erforderlich. Bei der Therapie, die sich bei der ketoazidotischen (DKA) und hyperglyk\u00e4misch-hyperosmolaren (HHS) Form nicht wesentlich unterscheidet, kommt dem Ausgleich des meist betr\u00e4chtlichen Fl\u00fcssigkeitsdefizits mit mehreren Litern einer physiologischen kristalloiden L\u00f6sung eine vorrangige Rolle zu. Bei den Elektrolyten ist insbesondere auf eine ausgeglichene Serum-Kalium-Konzentration zu achten. Normal-Insulin oder rasch wirksame Analoga k\u00f6nnen initial als i.v.-Bolus verabreicht werden, in der Folge jedoch kontinuierlich \u00fcber einen Perfusor. Die Umstellung auf eine subkutane Insulintherapie soll erst bei ausgeglichenem S\u00e4ure-Basen-Haushalt und zufriedenstellender Glyk\u00e4mie erfolgen.<\/jats:p>","DOI":"10.1007\/s00508-025-02694-5","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:12:29Z","timestamp":1779315149000},"page":"303-307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapie der akuten diabetischen Stoffwechselentgleisungen bei Erwachsenen (Update 2026)","Treatment of acute diabetic metabolic crises in adults (Update 2026)"],"prefix":"10.1007","volume":"138","author":[{"given":"Michael","family":"Resl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Kaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Sourij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Clodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Schneewei\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Luger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"issue":"7","key":"2694_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2337\/dc09-9032","volume":"32","author":"AE Kitabchi","year":"2009","unstructured":"Kitabchi\u00a0AE, et\u00a0al. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32(7):1335\u201343.","journal-title":"Diabetes Care"},{"issue":"1","key":"2694_CR2","first-page":"109","volume":"26","author":"AE Kitabchi","year":"2003","unstructured":"Kitabchi\u00a0AE, et\u00a0al. Hyperglycemic crises in patients with diabetes mellitus. Diabetes Care. 2003;26(1):109\u2013S17.","journal-title":"Diabetes Care"},{"issue":"6","key":"2694_CR3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00063-012-0114-1","volume":"107","author":"S Schneider","year":"2012","unstructured":"Schneider\u00a0S. Hyperglycemic crisis in patients with diabetes mellitus. Med Klin Intensivmed Notfmed. 2012;107(6):435\u20139.","journal-title":"Med Klin Intensivmed Notfmed"},{"issue":"4","key":"2694_CR4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nrendo.2016.15","volume":"12","author":"G Umpierrez","year":"2016","unstructured":"Umpierrez\u00a0G, Korytkowski\u00a0M. Diabetic emergencies\u2014Ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol. 2016;12(4):222\u201332.","journal-title":"Nat Rev Endocrinol"},{"key":"2694_CR5","volume-title":"Endotext","author":"AR Gosmanov","year":"2000","unstructured":"Gosmanov\u00a0AR, et\u00a0al. Hyperglycemic crises: diabetic ketoacidosis (DKA), and hyperglycemic hyperosmolar state (HHS). In: De Groot\u00a0LJ, et\u00a0al., Hrsg. Endotext. 2000."},{"key":"2694_CR6","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1056\/NEJMc1701990","volume":"376","author":"M Fralick","year":"2017","unstructured":"Fralick\u00a0M, Schneeweiss\u00a0S, Patorno\u00a0E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N\u00a0Engl J Med. 2017;376:2300\u20132.","journal-title":"N Engl J Med"},{"issue":"1","key":"2694_CR7","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s00508-018-1423-z","volume":"131","author":"S Kaser","year":"2019","unstructured":"Kaser\u00a0S, et\u00a0al. Therapie der akuten diabetischen Stoffwechselentgleisungen bei Erwachsenen (Update 2019). Wien Klin Wochenschr. 2019;131(1):196\u20139.","journal-title":"Wien Klin Wochenschr"},{"key":"2694_CR8","volume-title":"Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults","author":"IE Hirsch","year":"2017","unstructured":"Hirsch\u00a0IE, et\u00a0al. Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults. 2017. UpToDate."},{"issue":"6","key":"2694_CR9","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1055\/s-0043-114493","volume":"143","author":"C Schumann","year":"2018","unstructured":"Schumann\u00a0C, Faust\u00a0M. Diabetic ketoacidosis and hyperosmolar hyperglycemic state. Dtsch Med Wochenschr. 2018;143(6):384\u201391.","journal-title":"Dtsch Med Wochenschr"},{"issue":"5","key":"2694_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11892-017-0857-4","volume":"17","author":"KK Dhatariya","year":"2017","unstructured":"Dhatariya\u00a0KK, Vellanki\u00a0P. Treatment of diabetic ketoacidosis (DKA)\/hyperglycemic hyperosmolar state (HHS): novel advances in the management of hyperglycemic crises (UK versus USA). Curr Diab Rep. 2017;17(5):33.","journal-title":"Curr Diab Rep"},{"issue":"4","key":"2694_CR11","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ecl.2013.07.001","volume":"42","author":"J Maletkovic","year":"2013","unstructured":"Maletkovic\u00a0J, Drexler\u00a0A. Diabetic ketoacidosis and hyperglycemic hyperosmolar state. Endocrinol Metab Clin North Am. 2013;42(4):677\u201395.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"2694_CR12","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jemermed.2013.03.040","volume":"45","author":"R Van Ness-Otunnu","year":"2013","unstructured":"Van Ness-Otunnu\u00a0R, Hack\u00a0JB. Hyperglycemic crisis. J\u00a0Emerg Med. 2013;45(5):797\u2013805.","journal-title":"J Emerg Med"},{"key":"2694_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3389\/fendo.2017.00106","volume":"8","author":"TTT Tran","year":"2017","unstructured":"Tran\u00a0TTT, et\u00a0al. Review of evidence for adult diabetic ketoacidosis management protocols. Front Endocrinol. 2017;8:106.","journal-title":"Front Endocrinol"},{"issue":"6","key":"2694_CR14","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.ajem.2010.02.004","volume":"29","author":"SA Mahler","year":"2011","unstructured":"Mahler\u00a0SA, Conrad\u00a0SA, Wang\u00a0H, Arnold\u00a0TC. Resuscitation with balanced electrolyte solution prevents hyperchloremic metabolic acidosis in patients with diabetic ketoacidosis. Am J Emerg Med. 2011;29(6):670\u20134.","journal-title":"Am J Emerg Med"},{"issue":"11","key":"2694_CR15","first-page":"1248","volume":"47","author":"M Ramanan","year":"2021","unstructured":"Ramanan\u00a0M, et\u00a0al. Sodium chloride or plasmalyte-148 evaluation in severe diabetic ketoacidosis: a\u00a0cluster, crossover, randomized, controlled trial. Intensive Care Med. 2021;47(11):1248\u201357.","journal-title":"Intensive Care Med"},{"key":"2694_CR16","doi-asserted-by":"publisher","unstructured":"Messina N, Anderson Z, Saravis L, Jimenez G, Plowman K, Harrington D. Revisiting diabetic ketoacidosis (DKA) fluid management: should normal saline be used? Cureus.17(1):e77739. https:\/\/doi.org\/10.7759\/cureus.77739.","DOI":"10.7759\/cureus.77739"},{"key":"2694_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrtlng.2022.03.014","author":"JA Catahay","year":"2022","unstructured":"Catahay\u00a0JA, et\u00a0al. Balanced electrolyte solutions versus isotonic saline in adult patients with diabetic ketoacidosis: a\u00a0systematic review and meta-analysis. Heart Lung. 2022; https:\/\/doi.org\/10.1016\/j.hrtlng.2022.03.014.","journal-title":"Heart Lung"},{"key":"2694_CR18","doi-asserted-by":"publisher","unstructured":"Alghamdi NA, Major P, Chaudhuri D, Tsui J, Brown B, Self WH, Semler MW, Ramaman M, Rochwerg B. Saline compared to balanced crystalloid in patients with diabetic ketoacidosis: a\u00a0systematic review and meta-analysis of randomized controlled trials. Crit Care Explor https:\/\/doi.org\/10.1097\/CCE0000000000000613.","DOI":"10.1097\/CCE0000000000000613"},{"key":"2694_CR19","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s00125-024-06183-8","volume":"67","author":"GE Umpierrez","year":"2024","unstructured":"Umpierrez\u00a0GE, Davis\u00a0GM, ElSayed\u00a0NA, Fadini\u00a0GP, Galindo\u00a0RJ, Hirsch\u00a0IB, et\u00a0al. Hyperglycemic crises in adults with diabetes: a\u00a0consensus report. Diabetologia. 2024;67:1455\u201379.","journal-title":"Diabetologia"},{"key":"2694_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3389\/fendo.2018.00109","volume":"9","author":"A Usman","year":"2018","unstructured":"Usman\u00a0A. Initial potassium replacement in diabetic ketoacidosis: the unnoticed area of gap. Front Endocrinol. 2018;9:109.","journal-title":"Front Endocrinol"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02694-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-025-02694-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02694-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:12:40Z","timestamp":1779315160000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-025-02694-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":20,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2694"],"URL":"https:\/\/doi.org\/10.1007\/s00508-025-02694-5","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"17 December 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Resl hat von folgenden Unternehmen, die z.\u202fT. auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Boehringer Ingelheim, Eli Lilly, Dexcom, Abbott. S.\u00a0Kaser hat von folgenden Unternehmen, die z.\u202fT. auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Boehringer Ingelheim, NovoNordisk, Eli Lilly, Sanofi, Boehringer Ingelheim, Amarin. H.\u00a0Sourij hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: Amarin, Amgen, AstraZeneca, Boehringer-Ingelheim, Bayer, Daiichi Sankyo, Eli Lilly, Novo Nordisk, Novartis, Sanofi, Sobi. M.\u00a0Clodi hat von folgenden Unternehmen, die auch f\u00f6rdernde Mitglieder der \u00d6DG sind, Forschungsunterst\u00fctzungen und\/oder Honorare erhalten: AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Sanofi-Aventis, Servier, Takeda. B.\u00a0Schneewei\u00df und A.\u00a0Luger geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}